Urology Times Newsletter

BLADDER CANCER

Adding immunotherapy in the form of atezolizumab (Tecentriq) to platinum-based chemotherapy extends progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic urothelial carcinoma, according to results from a phase III study.

Read their column

Survival rates appear comparable for robotic, open cystectomy

“In treating a lethal disease such as muscle-invasive bladder cancer, our efforts must remain squarely focused on improving long-term disease control and survival,” writes Badar M. Mian, MD.

Read their column

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

Visit a Cysview® Reference Center in TX, OH, or CA

See hexaminolevulinate HCl in action in the operating room or clinic setting. Get answers and tips from an expert user. Travel and meal expenses are reimbursed. RSVP to discuss available dates and locations.